• EU CHMP backed Keytruda with Padcev for perioperative use in resectable muscle-invasive bladder cancer; European Commission decision due in Q4 2026.
• Recommendation follows Phase 3 KEYNOTE-B15, showing event-free survival hazard ratio 0.53; overall survival hazard ratio 0.65 versus chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609180655BIZWIRE_USPR_____20260917_BW438970) on September 18, 2026, and is solely responsible for the information contained therein.